TG Therapeutics Launches Phase 2 Study

TG Therapeutics announced an investigator-initiated second phase study evaluating the safety and efficacy of TGR-1202 in combination with ibrutinib in treating relapsed or refractory Diffuse Large B-cell Lymphoma.

The study, conducted at the University of Nebraska Medical Center, will also explore correlative analyses related to the combination. The company and its partner Janssen Pharmaceuticals will each provide drug and equally share study-related costs.

Leave a Comment